OPK

OPKO is a serially unprofitable pharma/diagnostics roll-up whose top line has fallen every year for five years — $1.77B (FY21) to $607M (FY25), down 14.9% in the latest year alone — while losses have never gone away. FY2025 net income swung to -$226M from -$53.2M, net margin is -37.2%, ROE is -17.8%, and the accumulated deficit has reached -$2.29B. This is not a temporary stumble; it is the structural signature of a company that, in its own words, 'historically [has] not generated sustained positive cash flow.' Operating cash flow was -$179M for the year, so the business is consuming roughly half its $364M cash balance every twelve months from operations alone.

The balance sheet looks deceptively calm — liabilities/equity of just 0.52x — but two things undercut it. First, $1.2B of the $1.27B stockholders' equity is goodwill and IPR&D, intangibles management itself flags for annual impairment testing; strip those and tangible equity is thin. Second, $344M of debt sits in current liabilities and the 10-K's contractual table shows a wall of obligations in 2029 ($91.99M, the 2029/2033 convertibles) and $246M of 2044 Notes thereafter. Management asserts cash is 'sufficient...beyond the next 12 months,' but concedes it 'may be required to use available cash resources sooner' and may need additional financing 'on favorable terms, or at all.' With shares outstanding already up 13% YoY, the most likely funding path — more equity — dilutes holders further at a $1.51 stock.